Written by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma. Europe’s medical cannabis industry is entering a
Jersey’s medical cannabis industry turned a profit for the first time in 2025, posting revenues of £12m, almost £50m in
Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis industry
German medicinal cannabis distributor Fette Pharma GmbH has reported the successful completion of a strategic restructuring, almost seven months after
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
Denmark’s medical cannabis Pilot Programme has seen patient numbers grow by more than 90% between Q2 2022 and Q2 2023.
Pharmaceutical cannabis industry sales are expected to grow by over 20% over the next four years, from $1.14b to $1.37b
We won’t spam you
